U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

Substance Class Protein
Created
by admin
on Tue Apr 01 18:01:08 GMT 2025
Edited
by admin
on Tue Apr 01 18:01:08 GMT 2025
Protein Type RECEPTOR
Protein Sub Type HYDROXYTRYPTAMINE RECEPTOR
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
6E2Z4UWILI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5-HT2B
Preferred Name English
5-HYDROXYTRYPTAMINE RECEPTOR 2B
Common Name English
5HT2B
Common Name English
Code System Code Type Description
UNIPROT
P41595
Created by admin on Tue Apr 01 18:01:08 GMT 2025 , Edited by admin on Tue Apr 01 18:01:08 GMT 2025
PRIMARY
FDA UNII
6E2Z4UWILI
Created by admin on Tue Apr 01 18:01:08 GMT 2025 , Edited by admin on Tue Apr 01 18:01:08 GMT 2025
PRIMARY
From To
1_128 1_207
1_350 1_353
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_30
Related Record Type Details
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
INHIBITOR -> TARGET
Ki
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
AGONIST->OFF-TARGET
5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.
WEAK AGONIST->OFF TARGET
Ki
RADIOLIGAND->TARGET
Ki
AGONIST -> TARGET
Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors
INHIBITOR -> TARGET
Acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors, with good selectivity over other serotonin receptor subtypes and slight preference for 5-HT2C over 5-HT2B.
ANTAGONIST
AGONIST -> TARGET
A full agonist.
Ki
INHIBITOR -> TARGET
AGONIST -> TARGET
BINDING
IC50
INHIBITOR -> TARGET
ANTAGONIST
INHIBITOR -> TARGET
Ki
PARTIAL AGONIST->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
Ki
INHIBITOR -> TARGET
BINDING
IC50
INHIBITOR -> TARGET
INHIBITOR -> TARGET
ANTAGONIST
INVERSE AGONIST->TARGET
IC50
AGONIST -> TARGET
BINDING
IC50
INVERSE AGONIST->TARGET
Ki
INHIBITOR -> TARGET
Ki
INHIBITOR -> TARGET
AGONIST -> TARGET
Ki
AGONIST -> TARGET
AGONIST -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
WEAK AGONIST->OFF TARGET
Emax,40%
AGONIST -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
Natural agonist
AGONIST->OFF-TARGET
5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.
INHIBITOR -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
Ki
INHIBITOR -> TARGET
Ki
INHIBITOR -> TARGET
Ki
RADIOLIGAND->TARGET
Kd
INHIBITOR -> TARGET
ANTAGONIST
AGONIST->OFF-TARGET
Responsible for valvular heart disease (VHD) with the administration of phentermine and fenfluramine (phen/fen) and dexfenfluramine1 led to the withdrawal of fenfluramine and dexfenfluramine from the marketplace in September 1997.
Ki
AGONIST->OFF-TARGET
We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.
Ki
AGONIST->OFF-TARGET
Indeed all drugs and drug metabolites that induce heart valvular disease in humans activate 5-HT2B receptors in vivo and in vitro and this activity is thought to be important for the development of fibrotic lesions upon chronic human administration.
Ki
AGONIST -> TARGET
Ki
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL